Hollywood And Horsepower Show with Mark Otto

Guest, Mary Beth Grey, Global Healthcare and Benefits Consultant

Navigating the "Tapeworm": Precision Medicine and the Future of US Healthcare

Hollywood & Horsepower: The Healthcare Maze

Featuring Mary Beth (MB) Grey • Top US Healthcare Consultant

Editorial Abstract

The Guest Profile

MB Grey

Top 50 Women Leaders (2025)

#MarshConsulting #PennStateAlum

Economic Reality

7.25y

Time for costs to DOUBLE

2nd

Highest Business Expense

"You need to drive your own bus on healthcare. The system is a money-generating machine, not a cure machine."

Core Strategic Insights

→

The 1967 Gap:

Standard chemo/radiation tech is decades old. Precision medicine (Immunotherapy/T-Cells) is the new frontier but often inaccessible.

→

The Power of Second Opinions:

Case study: 8/10 patients had treatment paths changed, and 2/10 were completely misdiagnosed at local facilities.

→

Employer-Led Revolution:

Since 60-70% of Americans get insurance via employers, CEOs/CFOs must mandate navigation tools and biomarker testing.

Critical Action Item

Demand Biomarker & Pharmacogenomic Testing immediately upon diagnosis to avoid ineffective, toxic treatments.

#PrecisionMedicine #SelfFundedInsurance #PatientAdvocacy

⏱ Reading Time: 4 min

This document summarizes a deep-dive conversation between host Mark Otto and award-winning healthcare consultant Mary Beth (MB) Grey. They explore the systemic failures of the American healthcare system, the unsustainable trajectory of corporate medical spending, and how precision medicine—specifically immunotherapy and biomarker testing—is revolutionizing outcomes for cancer and chronic illness.

The Economic Crisis of Employer-Sponsored Healthcare

The American healthcare system is currently facing an affordability crisis that threatens the profitability of the entire business sector. MB Grey highlights that healthcare is now the second-highest expense for most businesses, with Warren Buffett famously labeling it the "tapeworm of American business profitability." Costs are currently seeing double-digit annual increases with no signs of slowing down. For a company with a $10 million healthcare spend, that cost is projected to double every 7.25 to 7.3 years. This creates a "misalignment" in the industry, where insurance carriers and pharmacy benefit managers (PBMs) often prioritize rebates and program fees over the goal of lowering the net cost of drugs for employers and their families.

The "Doubling Effect" of Healthcare Spend

Based on current 10-12% annual increases:

Year 0

$10M

➔

Year 7.3

$20M

"The tapeworm of American business profitability." — Warren Buffett

The Rise of Early-Onset Illness and Environmental Factors

A significant and concerning trend in the US is the surge in early-onset cancer, particularly among individuals under the age of 30, which has risen by 30% in the last five to eight years. While genetics haven't changed, the environment has; experts point to the prevalence of plastics in food packaging and the ingestion of microparticles as potential drivers. This shift is particularly challenging for employers because these patients are part of the active workforce, requiring different strategies than those used for the Medicare-aged population. Furthermore, the system remains fragmented; it often takes 17 years for a proven medical advancement to trickle down into common clinical practice at local hospitals.

Precision Medicine: The "George Jetson" vs. "Fred Flintstone" Gap

MB Grey uses a "Jetson vs. Flintstone" analogy to describe the gap between cutting-edge medical technology and antiquated employer benefit plans. While many hospitals still rely on chemotherapy and radiation protocols developed in 1967, precision medicine offers a more effective path. This includes pharmacogenomic testing (a simple mouth swab to determine drug compatibility) and immunotherapy. A landmark breakthrough by Nobel laureate Jim Allison discovered how to strip proteins off cancer cells so the body’s own T-cells can identify and destroy them. This "precision" approach ensures patients get the right treatment the first time, avoiding the "hit or miss" nature of traditional oncology.

Precision Medicine vs. Traditional Care

Feature

Traditional (1967)

Precision (Modern)

Approach

One-size-fits-all

Genomic-based

Method

Chemo / Radiation

Immunotherapy / T-Cells

Accuracy

Trial and Error

Biomarker Testing

Advocacy and Alternative Success Stories

The discussion emphasizes that patients must be their own advocates. Success stories, such as the use of immunotherapy to save the world-champion horse "Alphabet Soup" and the recovery of a patient with stage four esophageal cancer through a university-led second opinion, illustrate that "where you go matters." Additionally, the conversation touches on the work of "No Fallen Heroes," which uses alternative treatments to help veterans and first responders overcome PTSD and traumatic brain injuries (TBI) caused by repetitive training explosions—treatments that are often more cost-effective and successful than conventional VA protocols but face regulatory hurdles in the US.

Key Data & Metrics

Cost Doubling: Healthcare spend for self-funded employers doubles approximately every 7.3 years.

Early-Onset Cancer: 30% increase in cancer for those under age 30 over the last 5-8 years.

Specialty Drugs: 2% of the population accounts for 60% of pharmacy costs due to high-cost specialty medications.

Misdiagnosis Rate: In a study by Walmart and Cleveland Clinic, 2 out of 10 patients were found to have been misdiagnosed with cancer by local providers.

Precision Testing: Pharmacogenomic tests cost only a few hundred dollars but can prevent months of ineffective treatment.

To-Do / Next Steps

Mandate Second Opinions: Employers should implement mandatory second-opinion programs for all cancer diagnoses to ensure accuracy.

Utilize Biomarker Testing: Patients diagnosed with cancer should immediately request biomarker analysis before starting traditional chemo/radiation.

Implement Navigation Tools: Companies must provide employees with navigation support to help them find "Centers of Excellence" like MD Anderson or Cleveland Clinic.

Explore Pharmacogenomics: Individuals on multiple medications should consider a pharmacogenomic mouth swab to identify potential drug-gene misalignments.

Advocate for Veterans: Support initiatives like "No Fallen Heroes" to bring proven TBI and PTSD treatments into mainstream medical acceptance.

Conclusion

The current US healthcare model is a "money-generating machine" that often prioritizes treatment over cures. However, by leveraging the power of the employer as the primary payer and embracing precision medicine, it is possible to bridge the gap between 1960s protocols and 21st-century technology. As MB Grey concludes, patients must "drive their own bus" and recognize that in healthcare, information and location are the ultimate determinants of survival.